Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Asembia Expands Collaboration with Pfizer Oncology


FLORHAM PARK, N.J., April 19, 2018 /PRNewswire/ -- Asembia members can now gain expanded access to Pfizer Oncology defined distribution oncology products for qualified hospital and health system clients. The new agreement includes Pfizer oncology products: Ibrance® (palbociclib), Bosulif® (bosutinib), Sutent® (sunitinib), Inlyta® (axitinib) and Xalkori® (crizotinib).

Asembia Logo (PRNewsfoto/Asembia)

"Asembia continues to work closely with Pfizer and all our arrangements to help hospitals and health systems give their patients access to these important medications," said Asembia CEO, Lawrence Irene.  "This opportunity to expand our current offerings for IDNs, hospitals and health systems enables our members to maintain continuity of care while offering these therapies locally."

Asembia's patient-centric care model is aimed at connecting all healthcare professionals to support patients throughout their course of treatment.  Hospital and health system clients also benefit from the company's cutting-edge technology solutions, including real-time data and analytics through Asembia's dynamic specialty pharmacy workflow platform, Asembia-1. The integrated web-based software platform optimizes specialty pharmacy operations, prescription workflow, and overall patient management. Asembia has developed this platform to seamlessly integrate with pharmacy dispensing systems and workflows used by specialty pharmacies across the country.

About Asembia
For more than a decade, Asembia has been working with member pharmacies, manufacturers, prescribers, payers, and other industry stakeholders to develop solutions for the high-touch specialty pharmaceutical service model. Through collaborative programs, contracting initiatives, patient support HUB services, and innovative technology platforms, Asembia is committed to positively impacting the patient journey. For more information, visit www.asembia.com.

Contact:
Bill Fitzgerald, VP Marketing
P: 973.564.8004
E: [email protected]

 

SOURCE Asembia


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: